Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q3 2018 · 10-Q
Revenue—
Net Income-$14.38M-$14.38MN/M vs Q3 2017 EPS Diluted-$0.63-$0.63N/M vs Q3 2017 Operating Income-$14,186,000N/M Operating Cash Flowderived-$13,725,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
Free Cash Flowderived-$13,744,000N/M ended Sep 30, 2018 · filed Nov 6, 2018 · 37 d after period end